Introduction
Chronic myeloid leukemia (CML) is a clonal malignancy of the hemopoietic system characterized by the presence of the Philadelphia chromosome (Ph). The Ph results from a reciprocal translocation between the long arms of chromosomes 9 and 22, resulting in the BCR-ABL fusion gene. 1, 2 The resultant p210 BCRÀABL protein has elevated and uncontrolled tyrosine kinase activity, resulting in the unregulated expansion of mature myeloid cells. 3, 4 Imatinib mesylate (Novartis Pharmaceuticals, Basel, Switzerland) is now the frontline therapy for Ph þ chronic phase (CP) CML. Imatinib is a small-molecule tyrosine kinase inhibitor, which competitively binds the ATP binding domain of BCR-ABL. Imatinib treatment results in cytogenetic and molecular remissions in the majority of patients with CP-CML. 5 However, residual leukemia has been detected in the primitive stem cell compartment in patients who have achieved complete cytogenetic remissions. 6, 7 Furthermore, despite achieving complete molecular remissions, discontinuation of imatinib therapy has been associated with disease recurrence in more than 50% of cases studied. [8] [9] [10] It has been shown that primitive CML cells have a reduced sensitivity to imatinib-induced apoptosis. 11 This has been attributed to increased expression of BCR-ABL, 11, 12 increased expression of efflux proteins 12, 13 and/or decreased expression of the organic cation transporter 1 (OCT-1) protein. 12 Previous studies from our laboratory 14 and those of others 15 have shown that imatinib transport is an active process, with influx primarily mediated by OCT-1. OCT-1 belongs to the solute carrier superfamily and is responsible for the distribution and elimination of organic cations in vivo. 16, 17 Using our established intracellular uptake and retention (IUR) assay, 14 we have shown that the functional activity of OCT-1 (OCT-1 Activity) in mononuclear cells (MNC) derived from CML patients is significantly related to their molecular response to imatinib treatment. 18 In addition, other studies have observed a relationship between OCT-1 mRNA levels and achievement of cytogenetic responses to imatinib. 19, 20 In addition to influx mechanisms, efflux mechanisms have been implicated as a cause of drug resistance in many malignancies, including leukemia. 21 Imatinib has been shown to be a substrate for both ABCB1 (MDR1, p-glycoprotein) and ABCG2 (breast cancer resistance protein) proteins belonging to the ATP-binding cassette (ABC transporter family. 15, 22, 23 However, there is conjecture as to whether imatinib acts as an inhibitor or substrate of these efflux proteins. 24, 25 Most recently, it has been suggested that imatinib interacts with ABCG2 as both an inhibitor and a substrate and these interactions are highly dose dependent. 26 The second generation tyrosine kinase inhibitor, nilotinib (Novartis Pharmaceuticals) was rationally designed to increase drug interactions with the ABL kinase domain 27 and as such is 10-50 times more potent than imatinib. 28, 29 Additionally, the transport of nilotinib into CML cells has been shown to be OCT-1 independent and occurs primarily through a passive process. 14 The aim of this study was to elucidate the mechanism of imatinib transport within CML progenitors and to identify the relationship between OCT-1 Activity and the maturation stage of leukemic cells.
Materials and methods

Patient samples
Peripheral Blood (PB) and bone marrow (BM) was obtained from newly diagnosed, CP-CML patients, before the commencement of imatinib therapy. All patients were within 6 months of diagnosis and all patients were imatinib naïve. Normal PB and BM were obtained from healthy volunteers. All samples were collected with informed consent in accordance with the Institutional Ethics approved protocols and with reference to the Declaration of Helsinki.
Cell isolation
MNC were isolated from PB and BM by density gradient centrifugation according to the manufacturer's instructions (Lymphoprep; Axis Shield, Oslo, Norway). CD34 þ cells were isolated from PB and BM MNC preparations using CD34 microbeads according to the manufacturer's instructions (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany). The CD34 þ cell purity was assessed using flow cytometry, and cell populations with purities o70% were discarded. More primitive CD34 þ 38À stem cells were isolated from the MACS purified CD34 þ population by fluorescence activated cell sorting. The CD34 þ 38À population was routinely o5% of the total CD34 þ population.
Owing to low CD34 þ cell numbers, not all assays were able to be performed on all CML samples. In most cases, imatinib IUR and OCT-1 Activity assays were preferentially performed. If sufficient CD34 þ cells remained nilotinib IUR and mRNA analyses were also carried out. For normal samples there was only enough CD34 þ cells to perform either imatinib IUR and OCT-1 Activity or mRNA analysis, hence the samples from these two assays are unmatched (Supplementary Table 1 ).
Kinase inhibitors
Imatinib mesylate (STI571), [14-C]-imatinib, nilotinib (AMN107) and [14-C]-nilotinib were kindly provided by Novartis Pharmaceuticals. Stock solutions of imatinib were prepared at a concentration of 1 and 10 mM in distilled water, sterile filtered and stored at À70 1C. Stock solutions of nilotinib were prepared at a concentration of 1 and 10 mM in dilmethylsulfoxide (Sigma Aldrich, Mannheim, Germany) sterile filtered and stored at 4 1C.
IUR assay
The IUR assays were conducted as described earlier.
14 All assays were performed in triplicate using 2 mM imatinib or nilotinib, and the IUR was expressed as ng of imatinib or nilotinib per 200 000 cells. The IUR of imatinib and nilotinib in the K562 cell line was used as a quality control for variation between assays. In cases in which the K562 IUR fell outside of mean ± 2 s.d. the assay results were discarded.
OCT-1 Activity and efflux inhibitors
The potent OCT-1 inhibitor prazosin (Sigma Aldrich, Steinheim, Germany) was used at 100 mM in the IUR assay. The OCT-1 Activity was expressed as the difference between the IUR in the absence and presence of prazosin, as described earlier. 18 Where IUR values in the presence of prazosin were equal or higher than the values in the absence of prazosin, these patients were scored as having negligible (0 ng/200 000 cells) OCT-1 Activity. The ABCB1 inhibitor PSC833 (Valspodar, kindly provided by Novartis Pharmaceuticals) and the ABCG2 inhibitor Ko143 (analog of fumitremorgin C, kindly provided by Professor John Allen, Centenary Institute, Sydney, Australia) were both used at 10 mM.
mRNA expression of OCT-1 and ABCB1
RNA was extracted from a minimum of 1 Â 10 6 cells using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). Complementary DNA was synthesized using Random Hexamers (GeneWorks Pty. Ltd, Hindmarsh, SA, Australia) and Superscript II Reverse Transcriptase (Invitrogen). OCT-1 and ABCB1 were amplified using PCR primer sequences as follows: OCT- 
Statistics
All statistics were performed using SigmaStat 3.0 software (SPSS Inc., Chicago, IL, USA). The Mann-Whitney Rank Sum or the Student's t-test was used to determine differences between experimental groups as appropriate. Correlations were performed using the Pearson Product Moment or Spearman Rank Order as appropriate.
Results and discussion
IUR of imatinib and OCT-1 Activity in CML cells
We have previously shown that the intracellular concentration of imatinib achieved in MNC in de novo CML patients correlates with their patient specific IC 50 and is therefore related to their degree of BCR-ABL inhibition. 14, 18 Here, we show that the IUR of imatinib is significantly reduced in the CD34 þ population compared with CD34À cells in 36 CP-CML patients (median CD34 þ : 20.3, CD34À: 25.3 ng/200 000 cells, Po0.001, Figure 1a ). This is in agreement with previous studies that show that CD34 þ cells exhibit reduced imatinib uptake compared to imatinib-sensitive K562 cells. 30 The addition of prazosin to the IUR assay inhibits the transport of imatinib through OCT-1 and hence provides a measure of OCT-1 Activity, which when measured in MNC is highly predictive of patient's molecular response to imatinib. 18 In this patient cohort, the OCT-1 Activity was found to be significantly reduced in the CD34 þ population compared to CD34À (median CD34 þ : 4.08, CD34À: 7.43 ng/200 000 cells, Po0.001, Figure 1c) . Furthermore, in the CD34 þ population, three patients exhibited an OCT-1 Activity below the level of detection.
To extend the association between OCT-1 function and maturation we isolated the more primitive CD34 þ 38À population in four CML patients and compared them to their corresponding CD34 þ 38 þ and CD34À populations. A stepwise increase in IUR and OCT-1 Activity was observed with increasing levels of maturity ( Table 1 ), suggesting that primitive status is associated with low OCT-1 Activity. However, these differences were not found to be significant because of low sample numbers.
Owing to the low yield of CD34 þ cells from primary material, investigation of the degree of BCR-ABL kinase inhibition mediated by imatinib in CD34 þ cells compared to CD34À was not possible. However, we have shown earlier a significant correlation between IC 50 and IUR, and IC 50 and OCT-1 Activity in the MNC compartment. 18 In addition, incomplete inhibition of BCR-ABL kinase activity in CML CD34 þ cells after imatinib treatment has previously been demonstrated.
11,31 Hence, we speculate that reduced intracellular accumulation of imatinib in primitive CML CD34 þ and CD34 þ 38À cells, mediated through a reduced OCT-1 Activity, may contribute to incomplete imatinib-induced BCR-ABL kinase inhibition, and thus increased survival of these cells, 11, 12 It is therefore possible that differences in BCR-ABL transcript number, and therefore kinase activity, between these two populations may have an effect on their OCT-1 function.
We have previously shown that the association between low OCT-1 Activity and poor molecular response in CML MNC can be overcome with increased doses of imatinib. 18 This observation led us to postulate that low OCT-1 Activity in primitive cells could also be overcome with increased imatinib dose. This hypothesis is supported by recent studies that showed that the intracellular concentration of imatinib in CML CD34 þ cells can be increased in a dose-dependent manner. 11, 30 Furthermore, Konig et al. 33 have demonstrated a dose-dependant increase in BCR-ABL inhibition and apoptosis in CML CD34 þ cells with increasing imatinib dose. However, more than 50% of these cells remained viable in the presence of 5 mM imatinib and Graham et al. 32 have shown that CML CD34 þ cells are insensitive up to 10 mM imatinib, which exceeds what is clinically achievable in patients. In addition, there are significant tolerability issues in many patients who attempt to dose escalate. Therefore, though increasing the dose of imatinib in patients may improve the intracellular concentration and hence targeting of primitive cells, this is unlikely to be sufficient to adequately eliminate this population.
IUR of imatinib and OCT-1 Activity in healthy individuals
In contrast to our observations in CML, no significant difference in the IUR of imatinib was observed between CD34 þ and CD34À cells derived from healthy donors (median IUR CD34 þ : 12.0, CD34À: 12.9 ng/200 000 cells, P ¼ 0.164, Figure 1b ). In addition, the OCT-1 Activity did not differ between normal CD34 þ and CD34À cells (median CD34 þ : 2.16, CD34À: 2.45 ng/200 000 cells, P ¼ 0.742, Figure 1d ). This suggests that increased OCT-1 Activity and imatinib IUR in mature CD34À cells may be a unique feature of CML, and related to the leukemic phenotype. This raises the possibility that BCR-ABL may have an effect on OCT-1 Activity.
OCT-1 mRNA
Studies by Crossman et al. 19 and Wang et al. 20 have identified OCT-1 mRNA expression as a determinant of patient response to imatinib treatment. In these studies, however, the majority of patients have received treatment before imatinib therapy, which may impact on OCT-1 expression. In contrast, we have previously shown that OCT-1 mRNA expression does not correlate with IC 50 or molecular response to imatinib. 18 We now show in 24 CP-CML patients that CML CD34 þ cells have a reduced OCT-1 mRNA expression compared with mature CML CD34À cells (median CD34 þ : 0.19 and CD34À: 2.87% of BCR, Po0.001, Figure 1e ). This is in agreement with the work of Jiang et al. 12 and supports the notion that this reduction in OCT-1 mRNA may contribute its reduced function in CML CD34 þ cells. However, this reduction in OCT-1 mRNA was also observed in CD34 þ cells derived from healthy donors (median CD34 þ : 0.02%, CD34À: 0.46%, P ¼ 0.009, n ¼ 11, Figure 1f) , and did not translate to a reduction in OCT-1 Activity (Figure 1d) . Furthermore, studies in Figure 2 show no correlation was observed between the level of OCT-1 mRNA expression and OCT-1 Activity in
. These data suggest that OCT-1 mRNA expression is not indicative of OCT-1 function. This is not unexpected given the OCT-1 protein is known to be highly posttranscriptionally regulated; with protein kinases A and C, calcium calmodulin and Src-like kinases identified as possible modulators of OCT-1 expression and function. 34, 35 In addition, polymorphisms within OCT-1 have been shown to affect transporter function. [36] [37] [38] Hence, functional Activity of the OCT-1 protein may be more relevant for patient response than OCT-1 mRNA expression.
Efflux of imatinib in CML progenitors
It has been reported that hematopoietic stem cells from CML patients express high levels of ABCB1 12 and ABCG2, 12, 13 raising the possibility that efflux may have a function in stem cell resistance to imatinib. Concordant with previous findings, 12 we show that CML CD34 þ cells express significantly higher ABCB1 mRNA than CD34À cells (median CD34 þ : 12.7%, CD34À: 1.6%, Po0.001, Figure 3a ) However, there remains conjecture as to whether imatinib is actually transported through these proteins. Studies reporting that imatinib is a substrate of ABCB1 15, 23, 39 and ABCG2 22, 26 have relied on the use of cell lines engineered to overexpress these proteins. Here, we have used primary CML CD34 þ cells and the ABCB1 inhibitor (PSC833) and the ABCG2 inhibitor (Ko143) in the IUR assay to assess imatinib transport through these pumps. We found neither drug had a discernable effect on the IUR of imatinib in CML CD34 þ cells (mean IUR: 11.0, PSC833: 11.3, Ko143: Figure 3b ). This agrees with previous studies that indicate that in the specific CML CD34 þ population imatinib efflux is not ABCB1 30 or ABCG2 13 dependant. Hence, despite high mRNA expression of these efflux pumps in CML progenitors, these transporters seem to have a minimal role in the efflux of imatinib in CML CD34 þ cells and are therefore not a major contributor to the reduced IUR of imatinib we have observed in these cells.
IUR of nilotinib in CML cells
To confirm the importance of OCT-1 in reduced imatinib accumulation in CML primitive cells, we performed comparisons in the IUR of the second generation tyrosine kinase inhibitor, nilotinib in 25 CML patients. We, 14 and others, 40 have previously reported that, unlike imatinib, the OCT-1 protein is not involved in nilotinib transport and speculate that its uptake occurs primarily through passive mechanisms. In contrast to imatinib, there was no significant difference in the IUR of nilotinib between CML CD34 þ and CD34À subsets (mean CD34 þ : 20.9, CD34À: 20.6 ng/200 000 cells, P ¼ 0.846, Figure 4 ) suggesting that passive uptake of nilotinib occurs at equivalent levels, irrespective of stage of differentiation. It would therefore be anticipated that nilotinib may better target CML progenitors in comparison to imatinib. However, it has been suggested that nilotinib is no more effective than imatinib in inducing apoptosis in CD34 þ cells. 31, 33 Speculatively, this may support the hypothesis that CML progentitors survive tyrosine kinase inhibitor treatment through BCR-ABL-independent mechanisms. 33, 41 Unfortunately, CD34 þ cell numbers prohibited further examination of this hypothesis in this cohort of patients.
In conclusion, reduced activity of the OCT-1 protein in CP-CML CD34 þ and CD34 þ 38À cells, resulting in low intracellular accumulation of imatinib, may contribute significantly to their persistence despite long-term imatinib treatment. These data highlight the contribution of drug transporters, particularly influx, to the imatinib resistant phenotype of primitive CML cells and emphasize the importance of understanding these transport mechanisms to optimize therapy and improve targeting of primitive cells. 
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